Nov 26 (Reuters) - PTC Therapeutics Inc :
* PTC THERAPEUTICS ANNOUNCES TOPLINE RESULTS OF CARDINALS TRIAL OF UTRELOXASTAT IN ALS PATIENTS
* PTC THERAPEUTICS INC - STUDY FAILED TO MEET PRIMARY AND SECONDARY EFFICACY ENDPOINTS
* PTC THERAPEUTICS INC - UTRELOXASTAT WAS DEMONSTRATED TO BE SAFE AND WELL TOLERATED IN CARDINALS TRIAL
* PTC THERAPEUTICS INC - FURTHER DEVELOPMENT OF UTRELOXASTAT NOT PLANNED
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.